-
Je něco špatně v tomto záznamu ?
Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry
J. Tužil, T. Mlčoch, J. Jirčíková, J. Závada, L. Nekvindová, M. Svoboda, M. Uher, Z. Křístková, J. Vencovský, K. Pavelka, T. Doležal,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem
- MeSH
- absentérství MeSH
- ankylózující spondylitida komplikace diagnóza farmakoterapie epidemiologie MeSH
- biologické přípravky terapeutické užití MeSH
- časové faktory MeSH
- dospělí MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- postižení statistika a číselné údaje MeSH
- posuzování pracovní neschopnosti MeSH
- prognóza MeSH
- průzkumy a dotazníky MeSH
- registrace statistika a číselné údaje MeSH
- stupeň závažnosti nemoci MeSH
- TNF-alfa antagonisté a inhibitory imunologie MeSH
- výkonnost * účinky léků MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
Objectives: To assess the role of short-term response to first anti-TNF in long-term prediction of disability.Methods: In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression.Results: 2,274 biologicals-naïve patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI < 4 (77.4%) and ASDAS-CRP < 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by ≈2.5-fold. ASDAS-CRP < 2.1 predicted non-disability better than BASDAI < 4 & CRP < 5 mg/L (p = 0.032). BASDAI < 4 & CRP < 5 mg/L was comparable to BASDAI < 4 (p = 0.941) and to BASDAI change by >50% or by >2 points (p = 0.902). ASDAS-CRP change >1.1 and >2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below €3,000 in those reaching ASDAS-CRP < 2.1.Conclusions: Low disease activity measured by ASDAS-CRP ≤ 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028549
- 003
- CZ-PrNML
- 005
- 20210114154225.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14712598.2020.1694900 $2 doi
- 035 __
- $a (PubMed)31736377
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Tužil, Jan $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic. 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
- 245 10
- $a Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry / $c J. Tužil, T. Mlčoch, J. Jirčíková, J. Závada, L. Nekvindová, M. Svoboda, M. Uher, Z. Křístková, J. Vencovský, K. Pavelka, T. Doležal,
- 520 9_
- $a Objectives: To assess the role of short-term response to first anti-TNF in long-term prediction of disability.Methods: In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression.Results: 2,274 biologicals-naïve patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI < 4 (77.4%) and ASDAS-CRP < 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by ≈2.5-fold. ASDAS-CRP < 2.1 predicted non-disability better than BASDAI < 4 & CRP < 5 mg/L (p = 0.032). BASDAI < 4 & CRP < 5 mg/L was comparable to BASDAI < 4 (p = 0.941) and to BASDAI change by >50% or by >2 points (p = 0.902). ASDAS-CRP change >1.1 and >2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below €3,000 in those reaching ASDAS-CRP < 2.1.Conclusions: Low disease activity measured by ASDAS-CRP ≤ 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.
- 650 _2
- $a absentérství $7 D000041
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biologické přípravky $x terapeutické užití $7 D001688
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a posuzování pracovní neschopnosti $7 D004185
- 650 _2
- $a postižení $x statistika a číselné údaje $7 D006233
- 650 12
- $a výkonnost $x účinky léků $7 D004526
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a registrace $x statistika a číselné údaje $7 D012042
- 650 _2
- $a stupeň závažnosti nemoci $7 D012720
- 650 _2
- $a ankylózující spondylitida $x komplikace $x diagnóza $x farmakoterapie $x epidemiologie $7 D013167
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a TNF-alfa $x antagonisté a inhibitory $x imunologie $7 D014409
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mlčoch, Tomáš $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic.
- 700 1_
- $a Jirčíková, Jitka $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic.
- 700 1_
- $a Závada, Jakub $u 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Institute of Rheumatology, Prague, Czech Republic.
- 700 1_
- $a Nekvindová, Lucie $u 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Institute of Biostatistics and Analyses, Ltd., Spinoff company of the Faculty of Medicine of the Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Svoboda, Michal $u Institute of Biostatistics and Analyses, Ltd., Spinoff company of the Faculty of Medicine of the Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Uher, Michal $u Faculty of Medicine of the Masaryk University, Institute of Biostatistics and Analyses, Brno, Czech Republic.
- 700 1_
- $a Křístková, Zlatuše $u Institute of Biostatistics and Analyses, Ltd., Spinoff company of the Faculty of Medicine of the Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Vencovský, Jiří $u 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Institute of Rheumatology, Prague, Czech Republic.
- 700 1_
- $a Pavelka, Karel $u 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. Institute of Rheumatology, Prague, Czech Republic.
- 700 1_
- $a Doležal, Tomáš $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic. Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 773 0_
- $w MED00181398 $t Expert opinion on biological therapy $x 1744-7682 $g Roč. 20, č. 2 (2020), s. 183-192
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31736377 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114154221 $b ABA008
- 999 __
- $a ok $b bmc $g 1608884 $s 1119729
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 20 $c 2 $d 183-192 $e 20191125 $i 1744-7682 $m Expert opinion on biological therapy $n Expert Opin Biol Ther $x MED00181398
- LZP __
- $a Pubmed-20210105
